

SEARCH REQUEST FORM

Requestor's
Name: _____

Serial
Number: _____

Date: _____

Phone: _____

Art Unit: _____

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

STAFF USE ONLY

Date completed: 12-21-01
Searcher: Beverly E 4994
Terminal time: 71
Elapsed time: _____
CPU time: _____
Total time: 15
Number of Searches: _____
Number of Databases: 1

Search Site

_____ STIC
_____ CM-1
_____ Pre-S

Type of Search

_____ N.A. Sequence
_____ A.A. Sequence
_____ Structure
_____ Bibliographic

Vendors

_____ ☒ IG
_____ STN
_____ Dialog
_____ APS
_____ Geninfo
_____ SDC
_____ DARC/Questel
_____ Other

YU, G.
09/836868

09/836868

~~FILE 'REGISTRY'~~ ENTERED AT 09:58:17 ON 21 DEC 2001

E MORINDA CITRIFOLIA/CN

L1 1 SEA ABB=ON PLU=ON "MORINDA CITRIFOLIA, EXT. "/CN

~~FILE 'CAPLUS'~~ ENTERED AT 09:58:46 ON 21 DEC 2001

L2 0 SEA ABB=ON PLU=ON L1

L3 11 S (CITRIFOLIA OR NONI OR INDIAN MULBERR?) (5A) (EXTRACT? OR
EXT##)

L3 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:584369 CAPLUS

DOCUMENT NUMBER: 135:352430

TITLE: Two novel glycosides from the fruits of Morinda
citrifolia (Noni) inhibit AP-1 transactivation
and cell transformation in the mouse epidermal
JB6 cell line

AUTHOR(S): Liu, Guangming; Bode, Ann; Ma, Wei-Ya; Sang,
Shengmin; Ho, Chi-Tang; Dong, Zigang

CORPORATE SOURCE: The Hormel Institute, University of Minnesota,
Austin, MN, 55912, USA

SOURCE: Cancer Res. (2001) 61(15), 5749-5756

CODEN: CNREAS; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The fruit juice of Morinda citrifolia (noni), a plant originally
grown in the Hawaiian and Tahitian islands, has long been used by
islanders to treat diseases, including cancer. Two novel
glycosides, 6-O-(.beta.-D-glucopyranosyl)-1-O-octanoyl-.beta.-D-
glucopyranose and asperulosidic acid, extd. from the juice
of noni fruits, were used to examine their effects on
12-O-tetradecanoylphorbol-13-acetate (TPA)- and epidermal growth
factor (EGF)-induced AP-1 transactivation and cell transformation in
mouse epidermal JB6 cells. The results indicated that both compds.
were effective in suppressing TPA- or EGF-induced cell
transformation and assocd. AP-1 activity. TPA- or EGF-induced
phosphorylation of c-Jun, but not extracellular signal-regulated
kinases or p38 kinases, was also blocked by the compds., indicating
that c-Jun N-terminal kinases were crit. in mediating TPA- or
EGF-induced AP-1 activity and subsequent cell transformation in JB6
cells.

REFERENCE COUNT: 48

REFERENCE(S): (1) Adler, V; J Biol Chem 1996, V271, P23304
CAPLUS
(2) Agadir, A; J Biol Chem 1999, V274, P29779
CAPLUS
(3) Amstad, P; Carcinogenesis (Lond) 1997, V18,
P479 CAPLUS
(4) Angel, P; Biochim Biophys Acta 1991, V1072,
P129 CAPLUS
(5) Angel, P; Cell 1987, V49, P729 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:167759 CAPLUS

DOCUMENT NUMBER: 134:192537

TITLE: Morinda citrifolia dietary fiber

INVENTOR(S): Wadsworth, John; Story, Stephen; Jensen, Jarakae

09/836868

PATENT ASSIGNEE(S): Morinda, Inc., USA
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015551	A1	20010308	WO 2000-US23489	20000825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6254913	B1	20010703	US 1999-384784	19990827
US 2001046550	A1	20011129	US 2001-829039	20010409

PRIORITY APPLN. INFO.: US 1999-384784 A 19990827

AB A dietary fiber product obtained from the Indian mulberry (*Morinda citrifolia*) plant and the process of extg. and purifying the fiber is disclosed. According to one embodiment, the Indian mulberry pulp is washed and sepd. from the juice by filtration. The wet pulp is pasteurized. The wet pulp can be further processed by drying. High fiber products can be prepd. by mixing the pulp with ingredients such as supplemental dietary fiber, water, sweeteners, flavoring agents, coloring agents, and nutritional ingredients.

REFERENCE COUNT: 5
REFERENCE(S): (1) Gaynor; US 5744187 A 1998
(2) McGillivray; US 5213836 A 1993
(3) Meer; US 4996051 A 1991
(4) Moniz; US 5288491 A 1994
(5) Thacker; US 5106634 A 1992

L3 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:167753 CAPLUS
DOCUMENT NUMBER: 134:212475
TITLE: Morinda citrifolia oil
INVENTOR(S): Wadsworth, John; Story, Stephen
PATENT ASSIGNEE(S): Morinda, Inc., USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015537	A1	20010308	WO 2000-US23394	20000825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH,				

Searcher : Shears 308-4994

09/836868

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6214351 B1 20010410 US 1999-384785 19990827

PRIORITY APPLN. INFO.: US 1999-384785 A 19990827

AB An essential oil product obtained from the Indian mulberry *Morinda citrifolia* plant and the process of extg. and purifying the oil is described. According to one embodiment, the seeds from the Indian mulberry fruit are dried, preferably to a moisture content less than 10%. The seeds are ground or shredded to facilitate the removal of natural occurring oil. The shredded or ground seed flakes are pressed to expel *Morinda citrifolia* oil. The remaining seed cake is then mixed with a food grade, non-polar extn. solvent such as hexane. The mixt. is heated for a sufficient length of time to complete the extn. process. The extn. solvent is then evapd. from the mixt. leaving the *Morinda citrifolia* oil. The oil is further refined, bleached, dried, and deodorized to remove free fatty acids and other unwanted components. An antioxidant, such as tocopheryl acetate, Pr gallate, TBHQ, or BHT can optionally be added to stabilize the oil for further processing or packaging.

REFERENCE COUNT: 4

REFERENCE(S): (1) Acosta; US 5922766 A 1999 CAPLUS
(2) Cooper; US 5736174 A 1998 CAPLUS.
(3) Goto; US 6139897 A 2000
(4) Moreau; US 5843499 A 1998 CAPLUS

L3 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:450093 CAPLUS

DOCUMENT NUMBER: 121:50093

TITLE: Isolation of 1-methoxy-2-formyl-3-hydroxyanthraquinone from *Morinda citrifolia* and neoplasm inhibitors containing the same

INVENTOR(S): Umezawa, Kazuo; Imoto, Masaya; Ooba, Shigeru;
Koyano, Takashi; Komyama, Yoshiko

PATENT ASSIGNEE(S): Umezawa Kazuo, Japan; Tonen Corp

SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06087736	A2	19940329	JP 1992-264311	19920907
AB				
Neoplasm inhibitors contg. the title compd. (I) as an active ingredient are claimed. A method for isolation of I contains extn. of <i>M. citrifolia</i> with solvents and the following purifn. A root of <i>M. citrifolia</i> (50 g) was ground and extd. 3 times with 200 mL CHCl ₃ each at room temp. and the obtained CHCl ₃ ext. was freeze-dried to give 0.7 g powder. The powder (200 mg) dispersed in CHCl ₃ was fractionated with silica gel column chromatog. eluting with 11:1, 10:1 and 5:1				

09/836868

mixts. of hexane and AcOEt to give an active fraction as eluate by the 5:1 mixt. The active fraction was dried, and the obtained 51.8 mg product was dissolved in MeOH to give 35.4 mg insol. fraction, which was crystd. in CH₂Cl₂ to give 12.6 mg I. IC₅₀ value of I against K-rasts-NRK cell was 7.50 .mu.g/mL at 33.degree. and 4.95 .mu.g/mL at 39.degree.. I also normalized cell morphol. of cancer cells.

L3 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:23170 CAPLUS

DOCUMENT NUMBER: 120:23170

TITLE: Induction of normal phenotypes in ras-transformed cells by damnacanthol from Morinda citrifolia

AUTHOR(S): Hiramatsu, Tomonori; Imoto, Masaya; Koyano, Takashi; Umezawa, Kazuo

CORPORATE SOURCE: Fac. Sci. Technol., Keio Univ., Yokohama, 223, Japan

SOURCE: Cancer Lett. (Shannon, Irel.) (1993), 73(2-3), 161-6

CODEN: CALEDQ; ISSN: 0304-3835

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors have screened tropical plant exts. for substances that induce normal morphol. in K-rasts-NRK cells. As a result the authors isolated an anthraquinone compd., damnacanthol, from the chloroform ~~ext.~~ of the root of Morinda citrifolia. Damnacanthol induced normal morphol. and cytoskeletal structure in K-rasts-NRK cells at the permissive temp., without changing the amt. and localization of Ras. The effect of damnacanthol was reversible, and the compd. had no effect on the morphol. of RSVts-NRK cells expressing the src oncogene. Thus, damnacanthol is a new inhibitor of ras function.

different

L3 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1987:623299 CAPLUS

DOCUMENT NUMBER: 107:223299

TITLE: Pharmaceuticals containing asperulosidic acid for hepatitis treatment

INVENTOR(S): Ogata, Yoshitake

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62132829	A2	19870616	JP 1985-272397	19851205

GI

09/836868




AB Pharmaceuticals for hepatitis treatment contain asperulosidic acid(I). Capsule compns. were prepd. by mixing I 5, microcryst. cellulose 80, corn starch 20, lactose 22, and polyvinylpyrrolidone 3 g.

L3 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1986:485300 CAPLUS
DOCUMENT NUMBER: 105:85300
TITLE: Separation of glycobismine A from *Glycosmis citrifolia*
INVENTOR(S): Furukawa, Hiroshi; Sato, Tadashi; Nagai, Yasushi; Kagei, Kengo
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60190780	A2	19850928	JP 1984-43897	19840309

GI



AB A new alkaloid glycobismine A (I) is isolated from root bark of *Glycosmis citrifolia* and its mol. structure is elucidated. The compd. is effective in curing skin itching and canker. Thus, dried *G. citrifolia* root bark (7 kg) was ~~extd.~~ with EtOH. The EtOH ext. was treated with CHCl₃/H₂O. The CHCl₃ fraction was concd. to syrup. The syrup was worked up by column chromatog. on silica gel, followed by silica gel TLC sepn. using benzene, diisopropyl ether, ether, acetone, and CHCl₃ as solvents to yield glycobismine A (180 mg).

L3 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1981:27438 CAPLUS
DOCUMENT NUMBER: 94:27438
TITLE: Isolation of .beta.-sitosterol and ursolic acid from *Morinda citrifolia* Linn
AUTHOR(S): Ahmad, Viqar Uddin; Bano, Shaheen
CORPORATE SOURCE: HEJ Postgrad. Inst. Chem., Univ. Karachi, Karachi, Pak.
SOURCE: J. Chem. Soc. Pak. (1980), 2(2), 71
CODEN: JCSPDF
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Ursolic acid (m.p. 286.degree.) and .beta.-sitosterol (m.p. 140-1.degree.) were isolated from alc. ~~exts.~~ of *M. citrifolia* leaves. ~~Compd. identity was confirmed by IR and mass spectra as well as by prepn. of derivs.~~

L3 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1979:520361 CAPLUS
DOCUMENT NUMBER: 91:120361
TITLE: Some chemical constituents of *Morinda citrifolia*
AUTHOR(S): Levand, Oscar; Larson, Harold O.
CORPORATE SOURCE: Dep. Chem., Univ. Guam, Agana, 96910, Guam
SOURCE: Planta Med. (1979), 36(2), 186-7
CODEN: PLMEAA; ISSN: 0032-0943
DOCUMENT TYPE: Journal
LANGUAGE: English

AB From ~~exts.~~ of dried fruit of *M. citrifolia*, asperuloside and glucose were identified by their acetyl derivs., i.e. asperuloside tetraacetate (m.p. 152-53.degree.) and .beta.-D-glucopyranose pentaacetate (m.p. 132-33.degree.), resp. Caproic and caprylic acids were also found, but in the steam ~~distillate~~ of ripe, sliced fruit.

L3 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1976:490215 CAPLUS
DOCUMENT NUMBER: 85:90215
TITLE: Flavone glycosides from the flowers of *Morinda citrifolia*
AUTHOR(S): Singh, Jagdamba; Tiwari, R. D.
CORPORATE SOURCE: Dep. Chem., Univ. Allahabad, Allahabad, India
SOURCE: J. Indian Chem. Soc. (1976), 53(4), 424
CODEN: JICSAH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Two flavone glycosides were isolated from the hot EtOH ext. of the flowers of *M. citrifolia*. 5,7-Acacetin-7-O-

09/836868

.beta.-D(+)-glucopyranoside and 5,7-dimethylapigenin-4'-O-.beta.-D(+)-galactopyranoside were identified by chem. means.

L3 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1941:14663 CAPLUS

DOCUMENT NUMBER: 35:14663

ORIGINAL REFERENCE NO.: 35:2331i,2332a

TITLE: The manufacture of "ikat" fabrics on the island of Rotti [Dutch East Indies]

AUTHOR(S): Buhler, Alfred

SOURCE: Verhandl. naturforsch. Ges. Basel (1939), Volume Date 1938-1939, 50, 32-97

DOCUMENT TYPE: Journal

LANGUAGE: German

AB Mainly a description of mech. details of native hand-manuf. of these cotton fabrics. Methods of dyeing blue or black with indigo, red with exts. of *Morinda citrifolia* or of Brazil wood (*Caesalpinia sappan*), and yellow with mixed exts. of *Curcuma domestica* with *Cudrania javanensis* or *Loranthus* are described. Exts. of other plants are employed as supplementary dyes. 6 references.

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO, CABA, AGRICOLA, CROPU, CROPB, LIFESCI' ENTERED AT 10:02:28 ON 21 DEC 2001)

L4
L5

46 S L3

33 DUP REM L4 (13 DUPLICATES REMOVED)

L5 ANSWER 1 OF 33 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 2001:374038 BIOSIS

DOCUMENT NUMBER: PREV200100374038

TITLE: *Morinda citrifolia* dietary fiber and method.

AUTHOR(S): Wadsworth, John J. (1); Story, Stephen P.; Jensen, C. Jarakae

CORPORATE SOURCE: (1) Orem, UT USA

ASSIGNEE: *Morinda*, Inc., Provo, UT, USA

PATENT INFORMATION: US 6254913 July 03, 2001

SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (July 3, 2001) Vol. 1248, No. 1, pp. No Pagination. e-file. ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

AB A dietary fiber product obtained from the Indian mulberry (*Morinda citrifolia*) plant and the process of **extracting** and purifying the fiber is disclosed. According to one embodiment, the Indian mulberry pulp is washed and separated from the juice by filtration. The wet pulp is pasteurized. The wet pulp can be further processed by drying. A high fiber products can be prepared by mixing the pulp with ingredients, such as supplemental dietary fiber, water, sweeteners, flavoring agents, coloring agents, and nutritional ingredients.

L5 ANSWER 2 OF 33 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 2001:443084 BIOSIS

DOCUMENT NUMBER: PREV200100443084

TITLE: *Morinda citrifolia* oil.

AUTHOR(S): Wadsworth, John J.; Story, Stephen P.

09/836868

ASSIGNEE: Morinda, Inc.
PATENT INFORMATION: US 6214351 April 10, 2001
SOURCE: Official Gazette of the United States Patent and
Trademark Office Patents, (Apr. 10, 2001) Vol. 1245,
No. 2, pp. No Pagination. e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English

AB An essential oil product obtained from the Indian mulberry (Morinda
citrifolia) plant and the process of **extracting**
and purifying the oil is disclosed. According to one embodiment, the
seeds from the Indian mulberry fruit are dried, preferably to a
moisture content less than 10%. The seeds are ground or shredded to
facilitate the removal of natural occurring oil. The shredded or
ground flakes are pressed to expel Morinda citrifolia oil. The
remaining seed cake is then mixed with a food grade, non-polar
extraction solvent such as hexane. The mixture is heated for a
sufficient length of time to complete the extraction process. The
extraction solvent is then evaporated from the mixture leaving the
Morinda citrifolia oil. The oil is further refined, bleached, dried,
and deodorized to remove free fatty acids and other unwanted
components. An antioxidant can optionally be added to stabilize the
oil for further processing or packaging.

L5 ANSWER 3 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2001-602546 [68] WPIDS
DOC. NO. CPI: C2001-178444
TITLE: Treatment of tinnitus using an extract of
Indian mulberry, optionally in
combination with other agents such as Ginkgo biloba
extract, vitamin C, lycopene or coenzyme Q10.
DERWENT CLASS: B04
INVENTOR(S): GIDLUND, B
PATENT ASSIGNEE(S): (GIDL-I) GIDLUND B
COUNTRY COUNT: 94
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001064231	A1	20010907	(200168)*	EN	17
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC					
MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE					
DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG					
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ					
PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU					
ZA ZW					
US 2001033871	A1	20011025	(200170)#		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001064231	A1	WO 2001-SE447	20010302
US 2001033871	A1	US 2000-186356P	20000302
		US 2001-796746	20010302

09/836868

PRIORITY APPLN. INFO: SE 2000-698 20000302; US 2001-796746
20010302

AN 2001-602546 [68] WPIDS
AB WO 200164231 A UPAB: 20011121
NOVELTY - An extract, which is derived from the fruits, leaves, bark
or roots of Morinda citrifolia L. (Indian mulberry), is used for
manufacturing a medicament for treatment of tinnitus in mammals.
ACTIVITY - Treatment of tinnitus.
MECHANISM OF ACTION - None given.
USE - The medicament is useful in treatment of tinnitus.
Dwg.0/0

L5 ANSWER 4 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2001-265850 [27] WPIDS
DOC. NO. CPI: C2001-080425
TITLE: Method of obtaining dietary fiber useful in e.g.
nutritional products involves filtering wet pulp
from juice of fiber plant and pasteurizing pulp.
DERWENT CLASS: A97 D13 E19
INVENTOR(S): JENSEN, C J; STORY, S P; WADSWORTH, J J; JENSEN, J;
STORY, S; WADSWORTH, J
PATENT ASSIGNEE(S): (MORI-N) MORINDA INC
COUNTRY COUNT: 94
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001015551	A1	20010308	(200127)*	EN	14
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC					
MW MZ NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE					
DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG					
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ					
PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU					
ZA ZW					
AU 2000073335	A	20010326	(200137)		
US 6254913	B1	20010703	(200140)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001015551	A1	WO 2000-US23489	20000825
AU 2000073335	A	AU 2000-73335	20000825
US 6254913	B1	US 1999-384784	19990827

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000073335	A Based on	WO 200115551

PRIORITY APPLN. INFO: US 1999-384784 19990827
AN 2001-265850 [27] WPIDS
AB WO 200115551 A UPAB: 20010518
NOVELTY - Morinda citrifolia (Indian mulberry plant) dietary fiber
(A) is obtained by filtering the wet pulp from the juice of Morinda
citrifolia (B) and pasteurizing the wet pulp. The pulp has a fiber

09/836868

content of 10-40 wt. %.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a high fiber dietary product comprising pulp of (B), supplemental dietary fiber and a sweetener.

USE - In cosmetics, nutritional products, dietary supplements as a flavoring and as a product itself.

ADVANTAGE - (A) has the nutritional and the health benefits.
Dwg. 0/0

L5 ANSWER 5 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2001-226656 [23] WPIDS
DOC. NO. CPI: C2001-067649
TITLE: Essential oil, used in massage oil, cosmetics and
candles, comprises oil **extracted** from
Morinda **Citrifolia** seeds.
DERWENT CLASS: B04 D21 D22 D23
INVENTOR(S): STORY, S P; WADSWORTH, J J; STORY, S; WADSWORTH, J
PATENT ASSIGNEE(S): (MORI-N) MORINDA INC
COUNTRY COUNT: 94
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001015537	A1	20010308	(200123)*	EN	15
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
US 6214351	B1	20010410	(200127)		
AU 2000073331	A	20010326	(200137)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001015537	A1	WO 2000-US23394	20000825
US 6214351	B1	US 1999-384785	19990827
AU 2000073331	A	AU 2000-73331	20000825

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000073331	A Based on	WO 200115537

PRIORITY APPLN. INFO: US 1999-384785 19990827

AN 2001-226656 [23] WPIDS

AB WO 200115537 A UPAB: 20010425

NOVELTY - Essential oil comprises oil **extracted** from
Morinda **Citrifolia** seeds is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included
for the extraction of an essential oil as above comprising: (a)
obtaining Morinda Citrifolia seeds that are dried to a moisture
content of less than 10 %; (b) cracking, flaking or grinding to form
ground seeds; and (c) pressing the ground seeds to expel Morinda

Citrifolia oil.

USE - The essential oil can be used in massage oils, cosmetics, or candles (claimed).

ADVANTAGE - The oil is easily extracted and can be stored for long periods of time.

Dwg.0/0

L5 ANSWER 6 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
 ACCESSION NUMBER: 2001-510208 [56] WPIDS
 DOC. NO. CPI: C2001-152910
 TITLE: Bathing composition containing **extract** of Morinda **citrifolia**.
 DERWENT CLASS: D21
 PATENT ASSIGNEE(S): (KANE) KANEBO LTD
 COUNTRY COUNT: 1
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 2001213758 A		20010807	(200156)*		4

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 2001213758 A		JP 2000-21470	20000131

PRIORITY APPLN. INFO: JP 2000-21470 20000131

AN 2001-510208 [56] WPIDS

AB JP2001213758 A UPAB: 20011001

NOVELTY - Bathing composition, comprising extract, crushed product or pressed product of Morinda citrifolia.

DETAILED DESCRIPTION - Bathing composition, comprising extract, crushed product or pressed product of Morinda citrifolia and also physically active ingredient.

USE - Useful as bathing agent giving good feeling after using.

Dwg.0/0

L5 ANSWER 7 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
 ACCESSION NUMBER: 2001-609745 [70] WPIDS
 DOC. NO. CPI: C2001-181794
 TITLE: Hair cosmetics for restoring hair growth and preventing dandruff, comprises extract, powder or pressed material of Morinda citrifolia, as active ingredient.
 DERWENT CLASS: D21
 PATENT ASSIGNEE(S): (KANE) KANEBO LTD
 COUNTRY COUNT: 1
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 2001213733 A		20010807	(200170)*		9

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

Searcher : Shears 308-4994

JP 2001213733 A

JP 2000-21472

20000131

PRIORITY APPLN. INFO: JP 2000-21472 20000131

AN 2001-609745 [70] WPIDS

AB JP2001213733 A UPAB: 20011129

NOVELTY - A hair cosmetics comprises extract, powder or pressed material of *Morinda citrifolia*, as active ingredient.

ACTIVITY - Endocrine-gen; antimicrobial; cytostatic; antiulcer. No test details are given in the specification.

MECHANISM OF ACTION - None given.

USE - For restoring hair growth and for preventing dandruff.

ADVANTAGE - The hair cosmetics containing powder, **extract** or pressed material of *Morinda citrifolia*, has excellent hair restoring effect and dandruff preventing effect. The cosmetics prevents split ends in hairs, effectively improves blood circulation and also exhibits excellent antimicrobial effect.

Dwg.0/0

L5 ANSWER 8 OF 33

MEDLINE

DUPLICATE 1

ACCESSION NUMBER: 2001431544 MEDLINE

DOCUMENT NUMBER: 21371894 PubMed ID: 11479211

TITLE: Two novel glycosides from the fruits of *Morinda citrifolia* (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line.

AUTHOR: Liu G; Bode A; Ma W Y; Sang S; Ho C T; Dong Z

CORPORATE SOURCE: The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.

CONTRACT NUMBER: CA74916 (NCI)

CA77646 (NCI)

CA81064 (NCI)

SOURCE: CANCER RESEARCH, (2001 Aug 1) 61 (15) 5749-56.

Journal code: CNF; 2984705R. ISSN: 0008-5472.

PUB. COUNTRY: United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200108

ENTRY DATE: Entered STN: 20010820

Last Updated on STN: 20010820

Entered Medline: 20010816

AB The fruit juice of *Morinda citrifolia* (noni), a plant originally grown in the Hawaiian and Tahitian islands, has long been used by islanders to treat diseases, including cancer. Two novel glycosides, 6-O-(beta-D-glucopyranosyl)-1-O-octanoyl-beta-D-glucopyranose and asperulosidic acid, **extracted** from the juice of **noni** fruits, were used to examine their effects on 12-O-tetradecanoylphorbol-13-acetate (TPA)- and epidermal growth factor (EGF)-induced AP-1 transactivation and cell transformation in mouse epidermal JB6 cells. The results indicated that both compounds were effective in suppressing TPA- or EGF-induced cell transformation and associated AP-1 activity. TPA- or EGF-induced phosphorylation of c-Jun, but not extracellular signal-regulated kinases or p38 kinases, was also blocked by the compounds, indicating that c-Jun N-terminal kinases were critical in mediating TPA- or EGF-induced AP-1 activity and subsequent cell transformation

in JB6 cells.

L5 ANSWER 9 OF 33 MEDLINE DUPLICATE 2
 ACCESSION NUMBER: 2001328763 MEDLINE
 DOCUMENT NUMBER: 21290190 PubMed ID: 11396135
 TITLE: Modulation of cancer cell multidrug resistance by an
 extract of *Ficus citrifolia*.
 AUTHOR: Simon P N; Chaboud A; Darbour N; Di Pietro A;
 Dumontet C; Lurel F; Raynaud J; Barron D
 CORPORATE SOURCE: Departement de Botanique, Pharmacognosie,
 Homeopathie, Institut des Sciences Pharmaceutiques et
 Biologiques, 8 Avenue Rockefeller, 69008 Lyon,
 France.
 SOURCE: ANTICANCER RESEARCH, (2001 Mar-Apr) 21 (2A) 1023-7.
 Journal code: 59L; 8102988. ISSN: 0250-7005.
 PUB. COUNTRY: Greece
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200107
 ENTRY DATE: Entered STN: 20010730
 Last Updated on STN: 20010730
 Entered Medline: 20010726

AB Multidrug resistance due to P-glycoprotein is a serious impediment to successful chemotherapy of cancer. Previous studies have shown that natural compounds such as prenyl flavonoids are able to modulate the multidrug resistance phenotype of P-glycoprotein-positive cancer cells. A fraction from the dichloromethane extract of a common Guadalupe Ficus, *Ficus citrifolia* was studied for its direct interaction with the purified C-terminal cytosolic domain of P-glycoprotein, and for its induced accumulation and cytotoxicity of vinblastine and daunomycin in two model cell lines overexpressing P-glycoprotein, namely K562/R7 and MESSA/Dx5. The fraction bound with high affinity to P-glycoprotein C-terminal cytosolic domain and was as efficient as cyclosporin A to increase intracellular accumulation of daunomycin in K562/R7 leukemic cells. Moreover, the fraction markedly enhanced the cytotoxic effect of vinblastine on the growth of MESSA/Dx5 cells. These results suggest that *Ficus citrifolia* possesses important therapeutic potential for improving the efficacy of cancer chemotherapy.

L5 ANSWER 10 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 2001386094 EMBASE
 TITLE: Evaluation of the flora of Puerto Rico for in vitro antiplasmodial and antimycobacterial activities.
 AUTHOR: Antoun M.D.; Ramos Z.; Vazques J.; Oquendo I.;
 Proctor G.R.; Gerena L.; Franzblau S.G.
 CORPORATE SOURCE: Dr. M.D. Antoun, School of Pharmacy, Medical Sciences
 Campus, University of Puerto Rico, San Juan 00936,
 Puerto Rico
 SOURCE: Phytotherapy Research, (2001) 15/7 (638-642).
 Refs: 15
 ISSN: 0951-418X CODEN: PHYREH
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 030 Pharmacology
 037 Drug Literature Index
 LANGUAGE: English

SUMMARY LANGUAGE: English

AB The emergence of resistant strains of *Plasmodium falciparum* and *Mycobacterium tuberculosis* underscores the need for novel drugs that are effective against these microorganisms. As part of our screening programme of the flora of Puerto Rico, we tested a number of ethanol extracts of higher plants for antiplasmodial and antimycobacterial activities. A total of 40 extracts belonging to 23 plant families and 37 species were tested for antiplasmodial activity. Five extracts demonstrated activity against *Plasmodium falciparum* in vitro (50%-100% parasite suppression at 5 .mu.g/mL). Another 63 extracts belonging to 30 plant families and 50 species were tested in vitro against *Mycobacterium tuberculosis*. Two extracts were found to be active, *Ficus citrifolia* and *Pisonia borinquena* (85% or more inhibition of microbial growth at 100 .mu.g/mL of extract).
Copyright .COPYRGT. 2001 John Wiley & Sons, Ltd.

L5 ANSWER 11 OF 33 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 2001:499690 BIOSIS

DOCUMENT NUMBER: PREV200100499690

TITLE: **Extracts of *Morinda citrifolia* (noni) exhibit selective anti-tumor activity against breast and colon carcinoma cell lines.**

AUTHOR(S): Csizsar, Katalin (1); Svertecki, Melinda; Ho, Chi-Tang; Fong, Sheri F. T.

CORPORATE SOURCE: (1) Rutgers University, New Brunswick, NJ USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2001) Vol. 42, pp. 634. print.
Meeting Info.: 92nd Annual Meeting of the American Association for Cancer Research New Orleans, LA, USA March 24-28, 2001
ISSN: 0197-016X.

DOCUMENT TYPE: Conference

LANGUAGE: English

SUMMARY LANGUAGE: English

L5 ANSWER 12 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2001175905 EMBASE

TITLE: [Noni juice - An amazing product?].
NONI - DER TAUSENDSSASSA?.

AUTHOR: Richter T.

CORPORATE SOURCE: Dr. T. Richter, Mohler-Apotheke, Burgstrasse 7, 97999 Igersheim, Germany

SOURCE: Zeitschrift fur Phytotherapie, (2001) 22/2 (93).
ISSN: 0722-348X CODEN: ZPHYDG

COUNTRY: Germany

DOCUMENT TYPE: Journal; Note

FILE SEGMENT: 037 Drug Literature Index

LANGUAGE: German

L5 ANSWER 13 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2001144569 EMBASE

TITLE: Traditional Hawaiian healing arts enrich conventional medical practices.

AUTHOR: Horowitz S.

SOURCE: Alternative and Complementary Therapies, (2001) 7/2 (68-73).
Refs: 21

ISSN: 1076-2809 CODEN: ACTHFZ
 COUNTRY: United States
 DOCUMENT TYPE: Journal; General Review
 FILE SEGMENT: 017 Public Health, Social Medicine and
 Epidemiology
 030 Pharmacology
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English

AB Hawaii, with its lovely environment, generally healthful diet, and traditional Hawaiian folk medicine practices centered around a venerable tradition of respectfully utilizing plants for healing, in combination with the culture's contributions from TCM and other traditional modalities, has much to offer contemporary integrative medicine. The islands certainly provide a setting that is conducive to reestablishing physical, mental, and spiritual balance in one's life. Medicine practiced in Hawaii is part of a trend that seeks to be more culturally sensitive to traditional mind-body-spirit beliefs and uses of botanicals and massage. It is hoped that Hawaiian's enviable longevity statistics will not be deflated by the ubiquitous influx of unhealthful fast food restaurants and mainland Western modes of handling stress. Among Hawaii's botanical treasures, noni, in particular, warrants further scientific investigation to confirm and utilize further this plant's potential as an immune-system booster and supplementary anticancer agent. Thus, it is also hoped that heightened environmental consciousness will help to preserve native plants for their functional and inherent value. In the words of a staff member of the R.W. Bliss Army Health Center in Fort Huachuca, Arizona: "Hawaii will probably continue its role in the transition of plants from traditional use to conventional use".

L5 ANSWER 14 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 2001235047 EMBASE
 TITLE: [Noni fruit].
 DIE NONI-FRUCHT.
 AUTHOR: Langer R.
 CORPORATE SOURCE: Dr. R. Langer, Institut fur Pharmakognosie,
 Universitat Wien, Pharmaziezentrum, Althanstrasse 14,
 A- 1090 Wien, Germany
 SOURCE: Deutsche Apotheker Zeitung, (14 Jun 2001) 141/24
 (61-63).
 Refs: 21
 ISSN: 0011-9857 CODEN: DAZE2
 COUNTRY: Germany
 DOCUMENT TYPE: Journal; (Short Survey)
 FILE SEGMENT: 037 Drug Literature Index
 LANGUAGE: German

L5 ANSWER 15 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 2001364886 EMBASE
 TITLE: [Noni - Questionable magic fruit from the South
 Seas].
 FRAGWURDIGE ZAUBERFRUCHT AUS DER SUDSEE.
 AUTHOR: Seidemann J.
 CORPORATE SOURCE: Dr. J. Seidemann, Neuendorfer Strasse 26/56, 14480
 Potsdam, Germany
 SOURCE: Pharmazeutische Zeitung, (4 Oct 2001) 146/40 (36-40).
 Refs: 47

09/836868

COUNTRY: Germany
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 037 Drug Literature Index
LANGUAGE: German

L5 ANSWER 16 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2000-248448 [22] WPIDS
DOC. NO. CPI: C2000-075320
TITLE: Preparation of composition based on extract of fruit of Polynesian plant Morinda Citrifolia, for use as invigorating-health improving drink, involves filtration, de-pectinization, heating and final filtration.
DERWENT CLASS: D13 D16
INVENTOR(S): TALON, C; TETUANUI, M
PATENT ASSIGNEE(S): (ROYA-N) ROYAL TAHITI NONI SARL
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
FR 2783137	A1	20000317	(200022)*		6

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
FR 2783137	A1	FR 1998-11288	19980910

PRIORITY APPLN. INFO: FR 1998-11288 19980910

AN 2000-248448 [22] WPIDS

AB FR 2783137 A UPAB: 20000508

NOVELTY - A process for preparing a composition, based on **extracts** of plant MORINDA CITRIFOLIA (common name: 'nono') includes gathering fruit, grinding, sieving, pectin removal, heating, filtration and pasteurizing.

DETAILED DESCRIPTION - Process of preparation of composition containing extracts of active substances of plant MORINDA CITRIFOLIA comprises following stages:

- (a) gathering fruit at its 3rd or 4th maturity stage;
- (b) grinding washed fruit in centrifuge/grinder;
- (c) collecting of juice and filtration to eliminate froth and solids, by pressing through sieve or using extractor-press;
- (d) enzymatic pectin removal by adding pectin removing agent;
- (e) progressive heating of obtained liquid to 60-80 deg. C, preferably 70 deg. C, and maintaining it at this temperature for 1 minute;
- (f) filtration; and
- (g) pasteurizing filtered juice at 80-90 deg. C, preferably at 70 deg. C for 1 minute.

INDEPENDENT CLAIMS are also included for:

- (1) juice of nono fruit obtained using process as claimed; and
- (2) use of juice of nono obtained as claimed, in pure form or diluted in other fruit juice, as health improving/invigorating drink.

USE - On its own or in mixture with various fruit juices, as

invigorating drink regulating natural body functions and having /
hypotensive, anti-ulcer, antiseptic, laxative etc. properties.

ADVANTAGE - The product is stable on storage, has no unpleasant
odor and retains properties of naturally obtained extracts.

Dwg.0/0

L5 ANSWER 17 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2000315612 EMBASE

TITLE: Novel glycosides from noni (*Morinda citrifolia*).

AUTHOR: Wang M.; Kikuzaki H.; Jin Y.; Nakatani N.; Zhu N.;
Csiszar K.; Boyd C.; Rosen R.T.; Ghai G.; Ho C.-T.

CORPORATE SOURCE: C.-T. Ho, Department of Food Science, Center for
Advanced Food Technology, Rutgers University, 65
Dudley Road, New Brunswick, NJ 08901-8520, United
States. ho@aesop.rutgers.edu

SOURCE: Journal of Natural Products, (2000) 63/8 (1182-1183).
Refs: 12

ISSN: 0163-3864 CODEN: JNPRDF

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Three new glycosides were isolated from the fruits of noni (*Morinda citrifolia*). Their structures were determined to be
6-O-(.beta.-D-glucopyranosyl)-1-O-octanoyl-.beta.-D-glucopyranose
(1), 6-O-(.beta.-D-glucopyranosyl)-1-O-hexanoyl-.beta.-D-
glucopyranose (2), and 3-methylbut-3-enyl 6-O-.beta.-D-
glucopyranosyl-.beta.-D-glucopyranoside (3) using MS and NMR
methods.

L5 ANSWER 18 OF 33 CABA COPYRIGHT 2001 CABI

ACCESSION NUMBER: 2001:106961 CABA

DOCUMENT NUMBER: 20013101436

TITLE: To trace the active compound in mengkudu
(*Morinda citrifolia*) with anthelmintic
activity against *Haemonchus contortus*
Penululusan senyawa aktif dari buah mengkudu
(*Morinda citrifolia*) dengan aktivitas
antelmintik terhadap *Haemonchus contortus*

AUTHOR: Murdiati, T. B.; Adiwinata, G.; Hildasari, D.

CORPORATE SOURCE: Balai Penelitian Veteriner, Jalan R.E.
Martadinata No.30, P.O. Box 151, Bogor 16114,
Indonesia.

SOURCE: Jurnal Ilmu Ternak dan Veteriner, (2000) Vol.
5, No. 4, pp. 255-259. 15 ref.
ISSN: 0853-7380

DOCUMENT TYPE: Journal

LANGUAGE: Indonesian

SUMMARY LANGUAGE: English

AB To trace the active compounds responsible for the anthelmintic
activity against *H. contortus*, the mengkudu fruit *Morinda*
citrifolia was continuously **extracted** into hexane,
chloroform, metanol and water, followed by in-vitro study on the
anthelmintic activity. The in-vitro activity was based on the
ability of the extracts to kill the worm and the ability of the
extracts to prevent egg development. The results suggests that
chloroform fraction which contains alkaloid and anthraquinon have

the highest anthelmintic activity and showed significant difference to that of the control ($P < 0.05$).

L5 ANSWER 19 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 1999298923 EMBASE

TITLE: An immunomodulatory polysaccharide-rich substance from the fruit juice of *Morinda citrifolia* (noni) with antitumour activity.

AUTHOR: Hirazumi A.; Furusawa E.

CORPORATE SOURCE: Dr. E. Furusawa, Department of Pharmacology, John A. Burns School of Medicine, University of Hawaii, 1960 East West Road, Honolulu, HI 96822, United States

SOURCE: Phytotherapy Research, (1999) 13/5 (380-387).

Refs: 36

ISSN: 0951-418X CODEN: PHYREH

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 016 Cancer
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
039 Pharmacy

LANGUAGE: English

SUMMARY LANGUAGE: English

AB The fruit juice of *Morinda citrifolia* (noni) contains a polysaccharide-rich substance (noni-ppt) with antitumour activity in the Lewis lung (LLC) peritoneal carcinomatosis model. Therapeutic administration of noni-ppt significantly enhanced the duration of survival of inbred syngeneic LLC tumour bearing mice. It did not exert significant cytotoxic effects in an adapted culture of LLC cells, LLC1, but could activate peritoneal exudate cells (PEC) to impart profound toxicity when co-cultured with the tumour cells. This suggested the possibility that noni-ppt may suppress tumour growth through activation of the host immune system. Concomitant treatment with the immunosuppressive agent, 2-chloroadenosine (Cl-Ade) or cyclosporin (cys-A) diminished its activity, thereby substantiating an immunomodulatory mechanism. Noni-ppt was also capable of stimulating the release of several mediators from murine effector cells, including tumour necrosis factor- α . (TNF- α), interleukin-1 β . (IL-1 β), IL-10, IL-12 p70, interferon- γ . (IFN- γ) and nitric oxide (NO), but had no effect on IL-2 and suppressed IL-4 release. Improved survival time and curative effects occurred when noni-ppt was combined with sub-optimal doses of the standard chemotherapeutic agents, adriamycin (Adria), cisplatin (CDDP), 5-fluorouracil (5-FU), and vincristine (VCR), suggesting important clinical applications of noni-ppt as a supplemental agent in cancer treatment.

L5 ANSWER 20 OF 33 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2000023673 EMBASE

TITLE: Evaluation of the flora of Puerto Rico for in vitro cytotoxic and anti-HIV activities.

AUTHOR: Antoun M.D.; Martinez E.; Caballero R.; Oquendo I.; Proctor G.R.; Weislow O.S.; McCloud T.G.; Kiser R.; Staley P.; Clanton D.

CORPORATE SOURCE: M.D. Antoun, Department Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan 00936, Puerto Rico

09/836868

SOURCE: Pharmaceutical Biology, (1999) 37/4 (277-280).
Refs: 23
ISSN: 1388-0209 CODEN: PHBIFC
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
016 Cancer
030 Pharmacology
037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB A total of 38 plant species belonging to 29 families were screened against HIV at the National Cancer Institute, Frederick Cancer Research and Development Center. In this assay, the virus is replicated in CEM SS cells, which are malignant cells of lymphocytic origin. It is therefore possible to measure the cytotoxicity of the extracts simultaneously, which is indicative of possible anticancer activity. Anti-HIV activity was found in eight extracts, whereas 13 extracts demonstrated cytotoxicity at an IC50 of 25 .mu.g/ml or less.

L5 ANSWER 21 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
DUPLICATE 3

ACCESSION NUMBER: 1996-439483 [44] WPIDS

DOC. NO. CPI: C1996-138146

TITLE: anti-helicobacter pylori agent contg.
extract of dried roots of *Morinda*
citrifolia - is used to treat recurring
infection diseases of upper respiratory tract
caused by *Helicobacter pylori* e.g. peptic ulcers.

DERWENT CLASS: B04

PATENT ASSIGNEE(S): (TERU) TERUMO CORP

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 08217686	A	19960827	(199644)*		3

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 08217686	A	JP 1995-20633	19950208

PRIORITY APPLN. INFO: JP 1995-20633 19950208

AN 1996-439483 [44] WPIDS

AB JP 08217686 A UPAB: 19961104

Agent contains **extract** of dried roots of *Morinda*
citrifolia.

Dried *Morinda citrifolia* roots are **extracted**
with organic solvent (e.g. EtOH, n-BuOH, pyridine, hexane, EtOAc,
acetone, pref. MeOH and CHCl3) for 1-2 days. Extract is evaporated
and used for producing of oral and parenteral prepsns. with
conventional carriers and additives. USE/ADVANTAGE - Used to
eradicate *helicobacter pylori*. Dosage is 0.10-3000 (pref. 1-1000)
mg/day for adult patients in 1-4 divided doses. Treats and prevents

09/836868

recurrence of upper digestive tract infectious diseases caused by *Helicobacter pylori* (e.g. peptic ulcer, gastritis and hepatitis, and gastric and hepatic cancers.

In an example, extract of dried *Morinda citrifolia* roots exhibited MIC of 6.25 mg/ml against *Helicobacter pylori* and showed acute oral toxicity, LD50 to male 5-week-old ICR mice of over 1000 mg/kg.

Dwg.0/0

L5 ANSWER 22 OF 33 JAPIO COPYRIGHT 2001 JPO
ACCESSION NUMBER: 1996-208461 JAPIO
TITLE: ANTI-HELICOBACTER PYRORI AGENT
INVENTOR: HASEGAWA HIROKAZU; KOYANO TAKASHI
PATENT ASSIGNEE(S): TERUMO CORP, JP (CO 365358)
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 08208461	A	19960813	Heisei	(6) A61K031-12

JP

APPLICATION INFORMATION

ST19N FORMAT: JP1995-20630 19950208
ORIGINAL: JP07020630 Heisei
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 96, No. 8

AN 1996-208461 JAPIO

AB PURPOSE: To obtain the subject agent having anti-*Helicobacter pylori* action and useful as an agent for the treatment and the relapse prevention of digestive ulcer, gastritis and hepatitis.
CONSTITUTION: This anti-*Helicobacter pylori* agent contains nordamnacanthal of formula I or damnacanthal of formula II. Nordamnacanthal is an orange acicular crystal having a melting point of 215.5-219.0.degree.C (recrystallized from CHCl3-hexane) and damnacanthal is a yellow acicular crystal having a melting point of 215.0-216.9.degree.C (recrystallized from CHCl3-hexane). The compounds of formula I and formula II can be produced by extracting dried roots of *Morinda citrifolia* with an organic solvent (preferably MeOH or CHCl3) or water at room temperature or under heating preferably after pulverizing the roots, filtering the extract and distilling out the solvent from the filtrate under reduced pressure. The daily administration rate of the agent for adult is generally 0.10-3,000mg, preferably 1-1,000mg divided in 1-4 divided portions.

L5 ANSWER 23 OF 33 SCISEARCH COPYRIGHT 2001 ISI (R)

ACCESSION NUMBER: 96:100186 SCISEARCH

THE GENUINE ARTICLE: TR362

TITLE: MUTAGENESIS OF SER(41) TO ALA INHIBITS THE ASSOCIATION OF GAP-43 WITH THE MEMBRANE SKELETON OF GAP-43-DEFICIENT PC12B CELLS - EFFECTS ON CELL-ADHESION AND THE COMPOSITION OF NEURITE CYTOSKELETON AND MEMBRANE

AUTHOR: MEIRI K F (Reprint); HAMMANG J P; DENT E W; BAETGE E E

CORPORATE SOURCE: SUNY HLTH SCI CTR, DEPT PHARMACOL, SYRACUSE, NY, 13210 (Reprint); SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, SYRACUSE, NY, 13210; CYTOTHERAPEUT INC,

09/836868

COUNTRY OF AUTHOR: PROVIDENCE, RI, 02906
SOURCE: USA
JOURNAL OF NEUROBIOLOGY, (FEB 1996) Vol. 29, No. 2,
pp. 213-232.
ISSN: 0022-3034.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: 63

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB To investigate the molecular basis for GAP-43 function in axon outgrowth, we produced a mutant, GAP-43 (Ala(41)), whose interaction with calmodulin in vitro was unaffected by increasing Ca²⁺ concentrations, and stably transfected it into GAP-43-deficient PC12B cells. Several lines that expressed wild-type or mutant protein at levels that resembled endogenous GAP-43 expression in PC12 controls were subcloned and characterized. GAP-43 (Ala(41)) was significantly more **extractable** with **Noni-det** P-40 and less tightly associated with the membrane skeleton than the wild-type protein. Furthermore, GAP-43 (Ala(41)) expression by PC12B cells profoundly affected their phenotype: First, observation of living cells using video-enhanced microscopy revealed irregular plasma membranes with numerous blebs and protrusions and neurites that appeared thin and varicose. Second, both the cells' ability to remain attached to laminin substrates and the amount of alpha 1 beta 1 integrin expressed on the cell surface was significantly decreased. Finally, peripherin transport, which is abnormal in PC12B cells, could be rescued by transfection of wild-type GAP-43 but not the GAP-43(Ala(41)) mutant. The phenotypic abnormalities resemble other cell types in which membrane skeleton/plasma membrane interactions have been functionally decoupled, and our results are consistent with the notion that these interactions may be abnormal in GAP-43(Ala(41))-expressing PC12B cells, either as a direct consequence of the mutation or arising secondarily to the altered availability of calmodulin in the growing neurite. (C) 1996 John Wiley & Sons, Inc.

L5 ANSWER 24 OF 33 JAPIO COPYRIGHT 2001 JPO
ACCESSION NUMBER: 1994-087737 JAPIO
TITLE: ANTI-AIDS AGENT
INVENTOR: KOYANO TAKASHI; IIDA KUMIKO; ASANO KAORU;
YOSHIZAWA MASAO; UMEZAWA KAZUO
PATENT ASSIGNEE(S): TONEN CORP, JP (CO 352374)
UMEZAWA KAZUO, JP (IN)

PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 06087737	A	19940329	Heisei	(5) A61K031-12

JP

APPLICATION INFORMATION

ST19N FORMAT: JP1992-264312 19920907
ORIGINAL: JP04264312 Heisei
SOURCE: PATENT ABSTRACTS OF JAPAN, Unexamined
Applications, Section: C, Sect. No. 1219, Vol.
18, No. 347, P. 88 (19940630)

AN 1994-087737 JAPIO

Searcher : Shears 308-4994

AB PURPOSE: To obtain an anti-AIDS agent having activity capable of suppressing proliferation of HIV in infected cell.
 CONSTITUTION: The anti-AIDS agent contains 1-methoxy-2-formyl-3-hydroxyanthraquinone expressed by the formula as an active ingredient. This compound is obtained by **extracting** Morinda **citrifolia** of a tropical plant, preferably with a non-polar solvent, especially a hydrocarbon solvent or a halogenated hydrocarbon solvent and concentrating the resultant extract once and then purifying the extract by chromatography. This anti-AIDS agent is mainly orally administered and its dose is 50-500mg/1kg body daily.

L5 ANSWER 25 OF 33 JAPIO COPYRIGHT 2001 JPO

ACCESSION NUMBER: 1994-087736 JAPIO
 TITLE: ANTICANCER AGENT
 INVENTOR: UMEZAWA KAZUO; IMOTO MASAYA; OBA SHIGERU; KOYANO TAKASHI; KOMIYAMA YOSHIKO
 PATENT ASSIGNEE(S): UMEZAWA KAZUO, JP (IN)
 TONEN CORP, JP (CO 352374)
 PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 06087736	A	19940329	Heisei	(5) A61K031-12

JP

APPLICATION INFORMATION

ST19N FORMAT: JP1992-264311 19920907
 ORIGINAL: JP04264311 Heisei
 SOURCE: PATENT ABSTRACTS OF JAPAN, Unexamined
 Applications, Section: C, Sect. No. 1219, Vol. 18, No. 347, P. 88 (19940630)

AN 1994-087736 JAPIO

AB PURPOSE: To obtain an anticancer agent containing 1-methoxy-2-formyl-3-hydroxyanthraquinone obtained from **extract** of Morinda **citrifolia** which is a tropical plant as an active ingredient.
 CONSTITUTION: Morinda citrifolia naturally grown or partially cultured in Southeast Asia is extracted with a solvent such as chloroform at ambient temperature to 60.degree.C to afford 1-methoxy-2-formyl-3-hydroxyanthraquinone of the formula. Using this compound as an active ingredient, the objective anticancer agent is provided. This active ingredient exhibits action capable of inhibiting action of ras cancer gene product. Namely, this active ingredient exhibits activity capable of inhibiting proliferation of cancer cell and normalizing the form of the cell.

L5 ANSWER 26 OF 33 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 1993:269525 BIOSIS
 DOCUMENT NUMBER: PREV199344131675
 TITLE: The effect of **noni** fruit **extract** (Morinda **citrifolia**, Indian **mulberry**) on thymocytes of BALB/C mouse.
 AUTHOR(S): Ganai, C. A.; Hokama, Y.
 CORPORATE SOURCE: Dep. Pathol., John A. Burns Sch. Med., Univ. Hawaii, Honolulu, HI 96822
 SOURCE: FASEB Journal, (1993) Vol. 7, No. 3-4, pp. A866.
 Meeting Info.: Meeting of the Federation of American

09/836868

Societies for Experimental Biology on Experimental
Biology '93 New Orleans, Louisiana, USA March
28-April 1, 1993
ISSN: 0892-6638.

DOCUMENT TYPE: Conference
LANGUAGE: English

L5 ANSWER 27 OF 33 SCISEARCH COPYRIGHT 2001 ISI (R)

ACCESSION NUMBER: 93:147964 SCISEARCH

THE GENUINE ARTICLE: KP975

TITLE: THE EFFECT OF **NONI FRUIT EXTRACT**
(**MORINDA-CITRIFOLIA, INDIAN**
MULBERRY) ON THYMOCYTES OF BALB/C MOUSE

AUTHOR: GANAL C A (Reprint); HOKAMA Y

CORPORATE SOURCE: UNIV HAWAII, JOHN A BURNS SCH MED, DEPT PATHOL,
HONOLULU, HI, 96822

COUNTRY OF AUTHOR: USA

SOURCE: FASEB JOURNAL, (23 FEB 1993) Vol. 7, No. 4, Part 2,
pp. A866.
ISSN: 0892-6638.

DOCUMENT TYPE: Conference; Journal

FILE SEGMENT: LIFE

LANGUAGE: ENGLISH

REFERENCE COUNT: 1

L5 ANSWER 28 OF 33 BIOSIS COPYRIGHT 2001 BIOSIS

ACCESSION NUMBER: 1993:400179 BIOSIS

DOCUMENT NUMBER: PREV199345059004

TITLE: Isolation of a ras-function inhibitor from an
extract of the tropical plant *Morinda*
citrifolia.

AUTHOR(S): Umezawa, K. (1); Hiramatsu, T.; Imoto, M.; Koyano, T.

CORPORATE SOURCE: (1) Dep. Applied Chem., Keio Univ., Yokohama 223
Japan

SOURCE: Proceedings of the American Association for Cancer
Research Annual Meeting, (1993) Vol. 34, No. 0, pp.
386.
Meeting Info.: 84th Annual Meeting of the American
Association for Cancer Research Orlando, Florida, USA
May 19-22, 1993
ISSN: 0197-016X.

DOCUMENT TYPE: Conference

LANGUAGE: English

L5 ANSWER 29 OF 33 CABA COPYRIGHT 2001 CABI

ACCESSION NUMBER: 94:108744 CABA

DOCUMENT NUMBER: 940308520

TITLE: A new anthraquinone glycoside from [heartwood
of] *Morinda citrifolia*

AUTHOR: Mala Srivastava; Singh, J.; Srivastava, M.

CORPORATE SOURCE: Department of Chemistry, University of
Allahabad, Allahabad 211 002, India.

SOURCE: International Journal of Pharmacognosy, (1993)
Vol. 31, No. 3, pp. 182-184. 10 ref.
ISSN: 0925-1618

DOCUMENT TYPE: Journal

LANGUAGE: English

AB *M. citrifolia* roots are used to relieve the pain caused by gout, and

09/836868

for their cathartic and febrifuge properties; leaves are used to treat wounds and ulcers, and the fruits are used to treat spongy gums, leucorrhoea and sapraemia. Physcion, morindone, and the new anthraquinone glycoside, physcion-8-O-[[alpha -L-arabinopyranosyl(1 right arrow 3)]][beta -D-galactopyranosyl(1 right arrow 6)]-beta -D-galactopyranoside], were isolated from the EtOH **extract** of the heartwood of *M. citrifolia* (collected from Allahabad, Uttar Pradesh, India), and identified from spectral analysis.

L5 ANSWER 30 OF 33 MEDLINE DUPLICATE 4
ACCESSION NUMBER: 94036765 MEDLINE
DOCUMENT NUMBER: 94036765 PubMed ID: 7693328
TITLE: Induction of normal phenotypes in ras-transformed cells by damnacanthal from *Morinda citrifolia*.
AUTHOR: Hiramatsu T; Imoto M; Koyano T; Umezawa K
CORPORATE SOURCE: Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Japan.
SOURCE: CANCER LETTERS, (1993 Sep 30) 73 (2-3) 161-6.
Journal code: CMX; 7600053. ISSN: 0304-3835.
PUB. COUNTRY: Ireland
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199311
ENTRY DATE: Entered STN: 19940117
Last Updated on STN: 19960129
Entered Medline: 19931126

AB We have screened tropical plant extracts for substances that induce normal morphology in K-rasts-NRK cells. As a result we isolated an anthraquinone compound, damnacanthal, from the chloroform **extract** of the root of *Morinda citrifolia*. Damnacanthal induced normal morphology and cytoskeletal structure in K-rasts-NRK cells at the permissive temperature, without changing the amount and localization of Ras. The effect of damnacanthal was reversible, and the compound had no effect on the morphology of RSVts-NRK cells expressing the src oncogene. Thus, damnacanthal is a new inhibitor of ras function.

L5 ANSWER 31 OF 33 MEDLINE DUPLICATE 5
ACCESSION NUMBER: 91172909 MEDLINE
DOCUMENT NUMBER: 91172909 PubMed ID: 1981810
TITLE: Analgesic and behavioural effects of *Morinda citrifolia*.
AUTHOR: Younos C; Rolland A; Fleurentin J; Lanhers M C; Misslin R; Mortier F
CORPORATE SOURCE: Laboratoire de Pharmacognosie, Universite de Metz, France.
SOURCE: PLANTA MEDICA, (1990 Oct) 56 (5) 430-4.
Journal code: P9F; 0066751. ISSN: 0032-0943.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199104
ENTRY DATE: Entered STN: 19910512
Last Updated on STN: 19950206
Entered Medline: 19910425

AB The traditional therapeutic indications for the use of *Morinda citrifolia* L. (Rubiaceae) have been investigated. The lyophilised aqueous **extract** of roots of *M. citrifolia* was evaluated for analgesic and behavioural effects in mice. The extract did not exhibit any toxic effects but did show a significant, dose-related, central analgesic activity in the writhing and hotplate tests; this effect was confirmed by the antagonistic action of naloxone. Furthermore, administration of *M. citrifolia* **extract** at high dosages decreased all behavioural parameters in the two compartment test, the light/dark choice situation test, and the staircase test; together with the induced sleeping time, these results are suggestive of sedative properties.

L5 ANSWER 32 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
 ACCESSION NUMBER: 1987-203558 [29] WPIDS
 DOC. NO. CPI: C1987-085328
 TITLE: Compsn. for treatment of hepatitis - contains asperulosidic acid **extracted** from *Morinda citrifolia* L bark as active component.
 DERWENT CLASS: A96 B02
 PATENT ASSIGNEE(S): (EISA) EISAI CO LTD
 COUNTRY COUNT: 1
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 62132829	A	19870616	(198729)*		3

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 62132829	A	JP 1985-272397	19851205

PRIORITY APPLN. INFO: JP 1985-272397 19851205

AN 1987-203558 [29] WPIDS

AB JP 62132829 A UPAB: 19930922

Remedy for hepatitis contains asperulosidic acid as an active substance.

The effect of asperulosidic acid was found in a rat acute hepatopathy model induced by D-galactosamine and having resemblance to human viral hepatitis histologically. Asperulosidic acid is **extracted** from *Morinda citrifolia* L. 35 kg of fresh bark of *Morinda citrifolia* L. is soaked in 25 lit. of methanol for 4 days. Methanol is removed from the extract and the obtd. 1 kg of residue is extracted with n-butanol. n-Butanol is removed from the extract and the obtained residue (170 g) is subjected to silica gel column chromatography. Fractions which exhibits blue in sulphuric acid reaction after TLC are collected and asperulosidic acid is recrystallised.

The structure of asperulosidic acid is of formula (I).

In an example asperulosidic acid (5 g), microcrystalline cellulose (80 g), corn starch (20 g), lactose (22 g) and polyvinylpyrrolidone (3 g) were granulated and filled in capsules to obtain the remedy.

USE/ADVANTAGE - Hepatitis is viral hepatitis, alcoholic hepatitis or drug-induced hepatitis.

0/0

L5 ANSWER 33 OF 33 CABA COPYRIGHT 2001 CABI
 ACCESSION NUMBER: 80:11733 CABA
 DOCUMENT NUMBER: 800381244
 TITLE: Some chemical constituents of Morinda
 citrifolia
 AUTHOR: Levand, O.; Larson, H. O.
 CORPORATE SOURCE: University of Guam, Agana, Guam 96910.
 SOURCE: Planta Medica, (1979) Vol. 36, No. 2, pp.
 186-187. 14 ref.
 ISSN: 0032-0943
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Asperuloside and glucose were identified in **extracts** of
 dried M. **citrifolia** fruits. Caproic acid and caprylic acid
 were also found.

~~FILE 'FSTA' ENTERED AT 10:04:51 ON 21 DEC 2001~~

L6 2 S L3

L6 ANSWER 1 OF 2 FSTA COPYRIGHT 2001 IFIS
 ACCESSION NUMBER: 2001(10):J2545 FSTA FS FSTA
 TITLE: Morinda citrifolia dietary fiber and method.
 AUTHOR: Wadsworth, J. J.; Story, S. P.; Jensen, C. J.
 CORPORATE SOURCE: Morinda Inc.
 SOURCE: United States Patent
 PATENT INFORMATION: US 6254913 B1 2001
 PRIORITY APPLN. INFO: US 99-384784 27 Aug. 1999 (Morinda, Provo, UT,
 USA)
 DOCUMENT TYPE: Patent (Patent)
 LANGUAGE: English

AB A dietary fibre product produced from the Indian mulberry (Morinda
citrifolia) plant, and a process of **extracting** and
 purifying the fibre, are described. The Indian mulberry pulp is
 washed and separated from its juice by filtration. The wet pulp is
 then pasteurized, and can be further processed by drying. A high
 fibre product can be obtained by mixing the pulp with ingredients
 such as supplemental dietary fibre, water, sweeteners, flavouring
 agents, coloring agents and nutritional ingredients.

L6 ANSWER 2 OF 2 FSTA COPYRIGHT 2001 IFIS
 ACCESSION NUMBER: 2000(06):H1431 FSTA FS FSTA
 TITLE: [Product based on **extracts** of Morinda
citrifolia.]
 AUTHOR: Talon, C.; Tetuanui, M.
 CORPORATE SOURCE: Royal Tahiti Noni sarl
 SOURCE: French Patent Application
 PATENT INFORMATION: FR 2783137 A1 2000
 PRIORITY APPLN. INFO: FR 98-11288 10 Sep. 1998
 DOCUMENT TYPE: Patent (Patent)
 LANGUAGE: French

AB A process is described for **extraction** of active principles
 from noni fruit (Morinda **citrifolia**); this
extract may be filtered, depectinated, heated, re-filtered
 and used directly as a beverage or blended with fruit juices.

=> fil hom

09/836868

FILE 'HOME' ENTERED AT 10:05:21 ON 21 DEC 2001

Searcher : Shears 308-4994

09/836868

(FILE ~~MEDLINE~~, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
~~JICST-EPLUS~~, JAPIO, CABA, AGRICOLA, CROPB, LIFESCI, FSTA'
ENTERED AT 10:38:06 ON 21 DEC 2001)

L11

O S L1

=> fil hom

FILE 'HOME' ENTERED AT 10:38:42 ON 21 DEC 2001